에이비온

203400KOSDAQ자연과학 및 공학 연구개발업

56.3 / 100

Reference Date: 2026-07-24

Financial Score21.0 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure12.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 25.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

ABION is a KOSDAQ-listed biopharmaceutical company specializing in the development of anti-cancer drugs and candidates based on companion diagnostics. Key pipelines include Vabametkib for non-small cell lung cancer, ABN101 (an interferon-beta-based antiviral), and ABN501 targeting Claudin3 protein in various cancers. Approximately 95.3% of its revenue comes from government research contracts.

Number of Employees

34people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

0.95Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-60.24Industry Average -32.093.5Point

1.9x industry avg (good)

Debt Ratio

7.16Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -173.6% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
에이비온, 우성윤 부사장 3만2620주 장내 매수 [공시록]
우성윤 부사장의 대규모 주식 매수로 회사의 파이프라인에 대한 신뢰와 주주 가치 향상 의지가 반영되어 긍정적인 시장 반응을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 718Won52-week high 4,10052-week low 627

1-month return0.0Point

1m -25.21% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-06
Positive최대주주변경을수반하는주식담보제공계약체결2026-07-03
Neutral주주총회소집결의 (임시주주총회)2026-07-02
Neutral주주명부폐쇄기간또는기준일설정2026-07-02
Neutral주식병합결정2026-07-02